ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting

    Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study  from the ARTIS and Danbio Registers        

    Johan Askling1, Lene Dreyer2, Merete Lund Hetland3, Lennart Jacobsson4, Lars-Erik Kristensen5, Bente Glintborg6, . ARTIS and DANBIO study groups7 and Karin Hellgren8, 1Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, 2Gentofte University Hospital, Hellreup, Denmark, 3Glostrup University Hospital, Glostrup, Denmark, 4Sahlgrenska Academy, Gothenburg, Sweden, 5Lund University, Lund, Sweden, 6Gentofte University Hospital, Gentofte, Denmark, 7Karolinska Institutet, stockholm, Sweden, 8Karolinska Institutet, Stockholm, Sweden

    Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…
  • Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting

    Biologics in Takayasu Arteritis: Preliminary Data from the French Registry

    Arsene Mekinian1, Chloe Comarmond2, Mathieu Resche Regon3, Tristan Mirault4, Jean-Emmanuel Kahn5, Marc Lambert6, Jean Sibilia7, Antoine Neel8, Miguel Hié9, Emmanuel Messas10, Pascal Cohen11, Geraldine Muller12, Sabine Berthier13, Zahir Amoura14, Isabelle Marie15, Christian Lavigne16, Marie Anne Vandenhende17, Hervé Devilliers18, Sébastien Abad19, Loic Guillevin20, Mohamed Hamidou21, Bertrand Godeau22, Patrice Cacoub23, Olivier Fain24 and David Saadoun2, 1DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, 2DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 3biostatistics Saint Louis Hospital, paris, France, 4HEGP vascular department, paris, France, 5Internal Medicine, Foch Hospital, Suresnes, France, 6Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, 7Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 8INTERNAL MEDICINE, NANTES, France, 9Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 10HEGP hospital Vascular and cardiology Department, paris, France, 11National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 12INTERNAL MEDICINE, DIJON, France, 13DIJON HOSPITAL, DIJON, France, 14Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 15CHU de Rouen, Rouen, France, 16CHU d'Angers, Angers, France, 17Internal Medicine, Bordeaux, France, 18Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, 19Hôpital Avicenne, Bobigny, France, 20Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, 21CHU Hôtel Dieu, Nantes, Nantes, France, 22Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 23Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 24Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France

    Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…
  • Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting

    Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register

    Emily Sutton1, Kath D. Watson2, David A. Isenberg3, Anisur Rahman4, David Jayne5, Caroline Gordon6, Ben Parker7, David P. D'Cruz8, Munther A. Khamashta9, Pamela Lutalo10, Peter Lanyon11, Benjamin Rhodes12, Bridget Griffiths13, Edward M. Vital14, Chee-Seng Yee15, Christopher Edwards16, Mohammed Akil17, Nicola Erb18, Athiveer Prabu19, Asad A. Zoma20, Neil McHugh21, Hazem Youssef22, Lee-Suan Teh23, Michael W. Beresford24 and Ian N. Bruce25, 1University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 3Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 4Centre for Rheumatology Research, University College London, London, United Kingdom, 5Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 6Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 8Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, 9Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 10Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, 11Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 12Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, 13Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 14NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, 15Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, 16Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 17Rheumatology Department, Sheffield South Yorkshire, United Kingdom, 18Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, 19Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, 20Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 21Rheumatology, Royal National Hospital, Bath, United Kingdom, 22Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, 23Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, 24Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 25Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials.  This may be due to…
  • Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting

    Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry

    Leslie R. Harrold1, George W. Reed1,2, Chitra Karki3, Robert Magner1, Ashwini Shewade4, Ani John4, Joel M. Kremer5 and Jeffrey D. Greenberg3,6, 1University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC., Southborough, MA, 3Corrona, LLC, Southborough, MA, 4Genentech, Inc, South San Francisco, CA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6NYU School of Medicine, New York, NY

    Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…
  • Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting

    Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4,5, Chitra Karki6, Robert Magner5, Joel M. Kremer7, Ashwini Shewade2 and Jeffrey D. Greenberg6,8, 1Columbia University, New York, NY, 2Genentech, Inc, South San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Corrona, LLC., Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6Corrona, LLC, Southborough, MA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8NYU School of Medicine, New York, NY

    Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology